T2 Biosystems Inc. (TTOO) Sets New 52-Week Low at $4.92
T2 Biosystems Inc. (NASDAQ:TTOO) shares reached a new 52-week low on Thursday . The company traded as low as $4.92 and last traded at $5.03, with a volume of 83,870 shares changing hands. The stock had previously closed at $5.11.
TTOO has been the topic of a number of recent research reports. WBB Securities raised shares of T2 Biosystems from a “speculative buy” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Wednesday, June 22nd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $15.00 price objective on shares of T2 Biosystems in a research note on Tuesday, June 21st. Canaccord Genuity reissued a “buy” rating on shares of T2 Biosystems in a research report on Tuesday, May 3rd. Leerink Swann reissued a “buy” rating on shares of T2 Biosystems in a research report on Monday, May 2nd. Finally, Zacks Investment Research raised shares of T2 Biosystems from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a research report on Tuesday, July 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $10.90.
The company’s market cap is $126.52 million. The company has a 50 day moving average of $8.17 and a 200 day moving average of $8.85.
T2 Biosystems (NASDAQ:TTOO) last issued its quarterly earnings data on Monday, May 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.54) by $0.01. The business had revenue of $1.10 million for the quarter. During the same quarter in the prior year, the company posted ($0.53) EPS. The company’s revenue was up 485.1% compared to the same quarter last year. On average, equities research analysts forecast that T2 Biosystems Inc. will post ($2.17) EPS for the current year.
In other T2 Biosystems news, SVP Rahul Dhanda sold 3,589 shares of the business’s stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $8.16, for a total transaction of $29,286.24. Following the transaction, the senior vice president now directly owns 3,589 shares of the company’s stock, valued at approximately $29,286.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
An institutional investor recently raised its position in T2 Biosystems stock. Aisling Capital LLC raised its position in T2 Biosystems Inc. (NASDAQ:TTOO) by 12.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,830,992 shares of the company’s stock after buying an additional 307,692 shares during the period. T2 Biosystems makes up approximately 5.3% of Aisling Capital LLC’s portfolio, making the stock its 6th largest position. Aisling Capital LLC owned approximately 13.89% of T2 Biosystems worth $30,971,000 as of its most recent SEC filing.
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.